News

Bristol-Myers Squibb has announced that results from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a selective, sodium glucose co-transporter2 inhibitor, produced clinically meaningful reductions across all

In an effort to better serve the batch, custom and specialty chemical industry, SOCMA members voted on March 19th to change the organisation’s name from the Synthetic Organic

Osiris Therapeutics has elected to end enrollment at 210 patients in its Phase III trial evaluating Prochymal for Crohn’s disease. The company believes there is a design flaw

Highlights FDA clearance and launch of second generation instrument platform, eSensor XT-8, with Warfarin sensitivity test CYP4F2 biomarker provides unique position in rapidly developing Warfarin testing market Installed

Galapagos, a drug discovery and development company, has initiated Phase I clinical development of its candidate drug GLPG0259 for rheumatoid arthritis. Galapagos said that the primary endpoints of

Italy-based biopharmaceutical company Gentium has reported encouraging preliminary unaudited top-line results from the Phase II/III European pediatric prevention clinical trial of defibrotide. The Phase II/III European pediatric prevention

Japan-based Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals North America, have established Takeda Canada, expanding the company’s North American presence. Takeda Canada will be

Eli Lilly and Company has announced inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering

Bayer has announced the launch of a new titration pack for patients with multiple sclerosis that is intended to make it easier for them to start Betaferon therapy.